Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

NCT04925284 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT04925284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04925284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Completed
Start date
June 7, 2021
Completion date
March 10, 2025
Enrollment
269 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, endometrial cancer, epithelial ovarian cancer, esophageal scc, hormone receptor-positive breast cancer, metastatic castration-resistant prostate cancer, non small cell lung cancer, pancreatic cancer, scchn, tissue factor-expressing solid tumors, triple negative breast cancer